Mackenzie, Scott CMoakes, Catherine ADoust, Ann MMol, Ben WDuncan, W ColinTong, StephenHorne, Andrew WWhitaker, Lucy H R2023-06-192023-06-192023-07Mackenzie, S C, Moakes, C A, Doust, A M, Mol, B W, Duncan, W C, Tong, S, Horne, A W & Whitaker, L H R 2023, 'Early (Days 1-4) post-treatment serum hCG level changes predict single-dose methotrexate treatment success in tubal ectopic pregnancy', Human reproduction (Oxford, England), vol. 38, no. 7, pp. 1261-1267. https://doi.org/10.1093/humrep/dead0890268-1161unpaywall: 10.1093/humrep/dead089https://hdl.handle.net/2164/20917Acknowledgements S.C.M. was supported by the South-East Scotland Academic Foundation Programme. Medical Research Council (MRC) Centre grants to the Centre for Reproductive Health (CRH) (G1002033 and MR/N022556/1) are also gratefully acknowledged. Funding This project was supported by funding from the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership (grant reference number 14/150/03). A.W.H. has received honoraria for consultancy for Ferring, Roche, Nordic Pharma and AbbVie. W.C.D. has received honoraria from Merck and Guerbet and research funding from Galvani Biosciences. L.H.R.W. has received research funding from Roche Diagnostics. B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). B.W.M. also reports consultancy for ObsEva and Merck and travel support from Merck. The other authors declare no competing interests.7729929engSDG 3 - Good Health and Well-beingtubal extopic pregnancymethotrexateHuman chorionic gonadotrophinbiomarkertreatment successProspective StudiesHumansPregnancy, Tubal/drug therapyTreatment OutcomePregnancyFemaleRetrospective StudiesMethotrexate/therapeutic useRG Gynecology and obstetricsNational Institute for Health Research (NIHR)14/150/03Medical Research Council (MRC)14/150/03G1002033MR/N022556/1Supplementary DataRGJournal article10.1093/humrep/dead089387